Company Overview
More
Shanghai Haohai Biotechnology Co., Ltd. is a Chinese company mainly engaged in biotechnology-related business. Its business includes the production and sales of biological agents and medical hyaluronic acid, bioengineering and pharmaceutical product research and development, and the provision of related services. Its products include orthopedic products, plastic surgery and wound care products, ophthalmic products, anti-adhesion and hemostatic products and so on. Orthopedic products include sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel. Plastic surgery and wound care products include recombinant human epidermal growth factor and so on. Ophthalmic products include ophthalmic viscoelasticity and eye moisturizer. Anti-adhesion and hemostatic products include collagen sponge and so on. The company mainly operates in mainland China.
CEO： Yongtai Hou
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
06826 HAOHAI BIOTEC
33.050+1.150+3.61%
YOY
Do not show
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Assets
Current assets
Inventory
45.83%
376.83M
39.05%
354.77M
12.02%
314.61M
-8.64%
264.05M
Accounts receivable
9.3%
399.71M
10.11%
375.21M
27.03%
401.98M
39.71%
397.49M
Insurance and other receivables-current assets
123.63%
32.85M
--
--
399.84%
61.39M
--
--
Advance deposits and other receivables
--
--
35.15%
74.84M
--
--
2.71%
100.53M
Cash and equivalents
-11.46%
2.7B
-6.2%
2.9B
-4.31%
2.9B
1.01%
3.14B
Secured deposit
--
--
-98.8%
614K
--
--
-98.77%
614K
Financial assets at fair value-current assets
--
--
-57.9%
6.38M
--
--
--
--
Special items of current assets
-45.02%
12.27M
--
--
-63.34%
6.14M
--
--
Total current assets
-4.91%
3.59B
-2.56%
3.71B
1.43%
3.79B
1.9%
3.9B
Non-current assets
Fixed assets
49.38%
794.05M
--
--
18.19%
633.68M
--
--
Property, plant and equipment
--
--
22.39%
1.2B
--
--
15.4%
1.09B
Construction in progress
-16.98%
386.92M
--
--
13.76%
490.71M
--
--
Associated company interest
--
--
-20.83%
3.45M
--
--
-26.75%
3.49M
Interests in Joint Venture
--
--
4.58%
47.96M
--
--
--
45.86M
long-term investment
6.41%
52.64M
--
--
2211.88%
92.04M
--
--
Financial assets at fair value-non-current assets
--
--
--
--
--
--
--
6.46M
Other investments
--
--
--
--
--
--
--
61.99M
Intangible assets
47.62%
842.35M
51.71%
613.4M
36%
803.23M
-0.3%
423.35M
Goodwill
11.28%
429.48M
5.55%
406.9M
5.43%
404.69M
0.38%
385.54M
Deferred tax assets
79.79%
50.85M
88.48%
49.36M
9.96%
34.49M
-24.69%
23.2M
Other illiquid assets
67.33%
102.54M
255.36%
130.93M
22.86%
12.52M
-8.97%
11.19M
Special items of non-current assets
39.78%
49.31M
29.8%
788.74M
-9.21%
39.96M
17.34%
645.21M
Total non-current assets
24.19%
3.27B
30.1%
3.24B
25.48%
3.02B
14.69%
2.7B
Total assets
7.05%
6.85B
10.35%
6.95B
10.84%
6.81B
6.76%
6.6B
Liabilities
Current liabilities
Accounts payable
72.21%
48.96M
65.04%
46.26M
199.31%
63.47M
36.99%
30.2M
Tax payable
-28.42%
19.41M
-94.03%
1.26M
31.13%
34.03M
44.59%
25.8M
Other payables and accrued expenses
7.92%
229.95M
33.81%
397.33M
0.45%
214.97M
5.89%
407.57M
Short-term borrowing
-97.52%
2M
--
--
-68.61%
25.37M
--
--
Bank loans and overdrafts
--
--
-51.63%
42.42M
--
--
-39.1%
48.54M
Special items of current liabilities
52.18%
72M
--
--
5.25%
63.76M
--
--
Total current liabilities
2.33%
425.2M
12.34%
487.27M
2.06%
428.79M
1.51%
512.11M
Net current assets
-5.8%
3.16B
-4.47%
3.23B
1.35%
3.37B
1.95%
3.39B
Total assets less current liabilities
7.38%
6.43B
10.2%
6.46B
11.49%
6.38B
7.23%
6.08B
Non-current liabilities
Long-term bank loan
1913.35%
9.6M
93.85%
39.49M
4546.69%
28.92M
-44.37%
17.85M
Long-term accounts payable
0%
4.5M
80.22%
8.11M
0%
4.5M
0%
4.5M
Deferred tax liability
68.99%
170.73M
54.39%
157.91M
49.84%
158.29M
1.49%
109.62M
Deferred income-non-current liabilities
115.41%
8.12M
165.29%
9.4M
385.15%
10.66M
220.31%
8.53M
Provision-non-current liabilities
--
--
--
1.77M
--
--
--
--
Other non-current liabilities
--
186.12M
--
186.12M
--
--
--
--
Special items of non-current liabilities
42.56%
31.21M
--
--
-6.91%
23.99M
--
--
Total non-current liabilities
211.61%
410.27M
208.19%
402.8M
63.16%
226.36M
-4.59%
140.49M
Total liabilities
52.68%
835.47M
57.69%
890.07M
17.23%
655.15M
0.13%
652.6M
Total assets less total liabilities
2.79%
6.02B
5.69%
6.06B
10.2%
6.16B
7.55%
5.94B
Total equity and non-current liabilities
7.38%
6.43B
10.2%
6.46B
11.49%
6.38B
7.23%
6.08B
Equity
Share capital
-0.45%
175.82M
-0.78%
175.82M
-0.78%
175.82M
-0.69%
176.62M
Reserve
--
--
3.67%
5.54B
--
--
7.88%
5.55B
Legal reserve
0%
88.92M
3.67%
5.54B
0%
88.92M
7.88%
5.55B
Capital reserve
-4.66%
3.08B
--
--
-2.84%
3.17B
--
--
Undistributed profit
14.85%
2.37B
--
--
23.69%
2.27B
--
--
Special items of shareholders' rights and interests
3.74%
46.61M
--
--
-103.87%
-1.74M
-97.92%
-44.91M
Shareholders' Equity
0.17%
5.62B
4.06%
5.71B
6.56%
5.7B
7.21%
5.68B
Non-controlling interest
61.93%
402.43M
42.44%
346.83M
92.62%
456.02M
15.26%
266.34M
Total equity
2.79%
6.02B
5.69%
6.06B
10.2%
6.16B
7.55%
5.94B
Total equity and total liabilities
7.05%
6.85B
10.35%
6.95B
10.84%
6.81B
6.76%
6.6B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)IASCAS (2007)IAS
Audit Opinions
--Unqualified Opinion----
Auditor
--Ernst & Young Huaming Accounting firm (Special General Partnership)----
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%